Structure-guided analysis of the human APOBEC3-HIV restrictome

Structure

Volumn 22, Issue 5, 2014, Pages 668-684

  Aydin, Halil ^a   Taylor, Matthew W ^a   Lee, Jeffrey E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; CYTOSINE DEAMINASE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; URACIL; VIF PROTEIN; VIRUS PROTEIN; APOBEC3 PROTEIN, HUMAN; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL ACTIVITY; BINDING SITE; CELL MEMBRANE; DEAMINATION; DNA BINDING; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE SYSTEM; MACROMOLECULE; NATURAL HOST; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA INTERACTION; REVERSE TRANSCRIPTION; REVIEW; STRUCTURE ANALYSIS; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PATHOGENICITY; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; BINDING SITES; CYTOSINE DEAMINASE; DNA, SINGLE-STRANDED; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEOCAPSID; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84899956157     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2014.02.011     Document Type: Review

References (168)

1. M.B. Adolph, J. Webb, and L. Chelico Retroviral restriction factor APOBEC3G delays the initiation of DNA synthesis by HIV-1 reverse transcriptase PLoS ONE 8 2013 e64196
2. J.S. Albin, R.S. LaRue, J.A. Weaver, W.L. Brown, K. Shindo, E. Harjes, H. Matsuo, and R.S. Harris A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif J. Biol. Chem. 285 2010 40785 40792
3. D. Bach, S. Peddi, B. Mangeat, A. Lakkaraju, K. Strub, and D. Trono Characterization of APOBEC3G binding to 7SL RNA Retrovirology 5 2008 54
4. C. Barnes, and H.C. Smith Apolipoprotein B mRNA editing in vitro is a zinc-dependent process Biochem. Biophys. Res. Commun. 197 1993 1410 1414
5. K. Bélanger, M. Savoie, M.C. Rosales Gerpe, J.-F. Couture, and M.-A. Langlois Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses Nucleic Acids Res. 41 2013 7438 7452
6. R.P. Bennett, J.D. Salter, X. Liu, J.E. Wedekind, and H.C. Smith APOBEC3G subunits self-associate via the C-terminal deaminase domain J. Biol. Chem. 283 2008 33329 33336
7. S. Best, P. Le Tissier, G. Towers, and J.P. Stoye Positional cloning of the mouse retrovirus restriction gene Fv1 Nature 382 1996 826 829
8. L. Betts, S. Xiang, S.A. Short, R. Wolfenden, and C.W. Carter Jr. Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex J. Mol. Biol. 235 1994 635 656
9. M. Binka, M. Ooms, M. Steward, and V. Simon The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H J. Virol. 86 2012 49 59
10. K.N. Bishop, R.K. Holmes, and M.H. Malim Antiviral potency of APOBEC proteins does not correlate with cytidine deamination J. Virol. 80 2006 8450 8458
11. K.N. Bishop, M. Verma, E.-Y. Kim, S.M. Wolinsky, and M.H. Malim APOBEC3G inhibits elongation of HIV-1 reverse transcripts PLoS Pathog. 4 2008 e1000231
12. H.P. Bogerd, H.L. Wiegand, B.P. Doehle, and B.R. Cullen The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains Virology 364 2007 486 493
13. M.-F. Bohn, S.M.D. Shandilya, J.S. Albin, T. Kouno, B.D. Anderson, R.M. McDougle, M.A. Carpenter, A. Rathore, L. Evans, and A.N. Davis et al. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain Structure 21 2013 1042 1050
14. R. Bransteitter, C. Prochnow, and X.S. Chen The current structural and functional understanding of APOBEC deaminases Cell. Mol. Life Sci. 66 2009 3137 3147
15. Y. Bulliard, P. Turelli, U.F. Röhrig, V. Zoete, B. Mangeat, O. Michielin, and D. Trono Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition J. Virol. 83 2009 12611 12621
16. A. Burnett, and P. Spearman APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker J. Virol. 81 2007 5000 5013
17. M.B. Burns, L. Lackey, M.A. Carpenter, A. Rathore, A.M. Land, B. Leonard, E.W. Refsland, D. Kotandeniya, N. Tretyakova, and J.B. Nikas et al. APOBEC3B is an enzymatic source of mutation in breast cancer Nature 494 2013 366 370
18. M.B. Burns, N.A. Temiz, and R.S. Harris Evidence for APOBEC3B mutagenesis in multiple human cancers Nat. Genet. 45 2013 977 983
19. I.-J.L. Byeon, J. Ahn, M. Mitra, C.-H. Byeon, K. Hercík, J. Hritz, L.M. Charlton, J.G. Levin, and A.M. Gronenborn NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity Nat. Commun. 4 2013 1890
20. M.A. Carpenter, E. Rajagurubandara, P. Wijesinghe, and A.S. Bhagwat Determinants of sequence-specificity within human AID and APOBEC3G DNA Repair (Amst.) 9 2010 579 587
21. A. Carr, and D.A. Cooper Adverse effects of antiretroviral therapy Lancet 356 2000 1423 1430
22. S. Cen, F. Guo, M. Niu, J. Saadatmand, J. Deflassieux, and L. Kleiman The interaction between HIV-1 Gag and APOBEC3G J. Biol. Chem. 279 2004 33177 33184
23. S. Cen, Z.-G. Peng, X.-Y. Li, Z.-R. Li, J. Ma, Y.-M. Wang, B. Fan, X.-F. You, Y.-P. Wang, and F. Liu et al. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G J. Biol. Chem. 285 2010 16546 16552
24. C. Chaipan, J.L. Smith, W.-S. Hu, and V.K. Pathak APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages J. Virol. 87 2013 444 453
25. K.R. Chaurasiya, M.J. McCauley, W. Wang, D.F. Qualley, T. Wu, S. Kitamura, H. Geertsema, D.S.B. Chan, A. Hertz, and Y. Iwatani et al. Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein Nat. Chem. 6 2014 28 33
26. L. Chelico, P. Pham, P. Calabrese, and M.F. Goodman APOBEC3G DNA deaminase acts processively 3′ - > 5′ on single-stranded DNA Nat. Struct. Mol. Biol. 13 2006 392 399
27. L. Chelico, E.J. Sacho, D.A. Erie, and M.F. Goodman A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV J. Biol. Chem. 283 2008 13780 13791
28. L. Chelico, C. Prochnow, D.A. Erie, X.S. Chen, and M.F. Goodman Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G J. Biol. Chem. 285 2010 16195 16205
29. K.-M. Chen, E. Harjes, P.J. Gross, A. Fahmy, Y. Lu, K. Shindo, R.S. Harris, and H. Matsuo Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G Nature 452 2008 116 119
30. G. Chen, Z. He, T. Wang, R. Xu, and X.-F. Yu A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G J. Virol. 83 2009 8674 8682
31. S.J. Chung, J.C. Fromme, and G.L. Verdine Structure of human cytidine deaminase bound to a potent inhibitor J. Med. Chem. 48 2005 658 660
32. J.M. Coffin, S.H. Hughes, and H.E. Varmus Retroviruses 1997 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY
33. S.G. Conticello, C.J.F. Thomas, S.K. Petersen-Mahrt, and M.S. Neuberger Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases Mol. Biol. Evol. 22 2005 367 377
34. Y. Dang, X. Wang, T. Zhou, I.A. York, and Y.-H. Zheng Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization J. Virol. 83 2009 8544 8552
35. Y. Dang, X. Wang, I.A. York, and Y.-H. Zheng Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity J. Virol. 84 2010 8561 8570
36. Y. Dang, R.W. Davis, I.A. York, and Y.-H. Zheng Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity J. Virol. 84 2010 5741 5750
37. J.P. Donahue, M.L. Vetter, N.A. Mukhtar, and R.T. D'Aquila The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation Virology 377 2008 49 53
38. C. Esnault, J. Millet, O. Schwartz, and T. Heidmann Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses Nucleic Acids Res. 34 2006 1522 1531
39. Y. Feng, and L. Chelico Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain J. Biol. Chem. 286 2011 11415 11426
40. Y. Feng, R.P. Love, and L. Chelico HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G J. Biol. Chem. 288 2013 6083 6094
41. J.L. Fribourgh, L.S. Wolfe, H.C. Nguyen, D.C. DeWitt, W. Zhang, X.-F. Yu, E. Rhoades, and Y. Xiong CBFβ plays a critical role facilitating the assembly of the Vif-Cul5 E3 ubiquitin ligase J. Virol. 88 2014 3309 3319
42. Y.N. Friew, V. Boyko, W.-S. Hu, and V.K. Pathak Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA Retrovirology 6 2009 56
43. A. Furukawa, T. Nagata, A. Matsugami, Y. Habu, R. Sugiyama, F. Hayashi, N. Kobayashi, S. Yokoyama, H. Takaku, and M. Katahira Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G EMBO J. 28 2009 440 451
44. A. Furukawa, K. Sugase, R. Morishita, T. Nagata, T. Kodaki, A. Takaori-Kondo, A. Ryo, and M. Katahira Quantitative analysis of location- and sequence-dependent deamination by APOBEC3G using real-time NMR spectroscopy Angew. Chem. Int. Ed. Engl. 53 2014 2349 2352
45. D. Gheysen, E. Jacobs, F. de Foresta, C. Thiriart, M. Francotte, D. Thines, and M. De Wilde Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells Cell 59 1989 103 112
46. K. Gillick, D. Pollpeter, P. Phalora, E.-Y. Kim, S.M. Wolinsky, and M.H. Malim Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination J. Virol. 87 2013 1508 1517
47. P. Gouet, E. Courcelle, D.I. Stuart, and F. Métoz ESPript: analysis of multiple sequence alignments in PostScript Bioinformatics 15 1999 305 308
48. C. Goujon, O. Moncorgé, H. Bauby, T. Doyle, C.C. Ward, T. Schaller, S. Hué, W.S. Barclay, R. Schulz, and M.H. Malim Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection Nature 502 2013 559 562
49. F. Guo, S. Cen, M. Niu, J. Saadatmand, and L. Kleiman Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication J. Virol. 80 2006 11710 11722
50. F. Guo, S. Cen, M. Niu, Y. Yang, R.J. Gorelick, and L. Kleiman The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA J. Virol. 81 2007 11322 11331
51. F. Guo, J. Saadatmand, M. Niu, and L. Kleiman Roles of Gag and NCp7 in facilitating tRNA(Lys)(3) Annealing to viral RNA in human immunodeficiency virus type 1 J. Virol. 83 2009 8099 8107
52. Y. Guo, L. Dong, X. Qiu, Y. Wang, B. Zhang, H. Liu, Y. Yu, Y. Zang, M. Yang, and Z. Huang Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif Nature 505 2014 229 233
53. G. Haché, M.T. Liddament, and R.S. Harris The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain J. Biol. Chem. 280 2005 10920 10924
54. E. Harjes, P.J. Gross, K.-M. Chen, Y. Lu, K. Shindo, R. Nowarski, J.D. Gross, M. Kotler, R.S. Harris, and H. Matsuo An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model J. Mol. Biol. 389 2009 819 832
55. R.S. Harris, S.K. Petersen-Mahrt, and M.S. Neuberger RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators Mol. Cell 10 2002 1247 1253
56. R.S. Harris, K.N. Bishop, A.M. Sheehy, H.M. Craig, S.K. Petersen-Mahrt, I.N. Watt, M.S. Neuberger, and M.H. Malim DNA deamination mediates innate immunity to retroviral infection Cell 113 2003 803 809
57. T. Hatziioannou, S. Cowan, S.P. Goff, P.D. Bieniasz, and G.J. Towers Restriction of multiple divergent retroviruses by Lv1 and Ref1 EMBO J. 22 2003 385 394
58. Z. He, W. Zhang, G. Chen, R. Xu, and X.-F. Yu Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction J. Mol. Biol. 381 2008 1000 1011
59. L.G. Holden, C. Prochnow, Y.P. Chang, R. Bransteitter, L. Chelico, U. Sen, R.C. Stevens, M.F. Goodman, and X.S. Chen Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications Nature 456 2008 121 124
60. R.K. Holmes, F.A. Koning, K.N. Bishop, and M.H. Malim APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G J. Biol. Chem. 282 2007 2587 2595
61. W.S. Hu, and H.M. Temin Retroviral recombination and reverse transcription Science 250 1990 1227 1233
62. J.F. Hultquist, J.A. Lengyel, E.W. Refsland, R.S. LaRue, L. Lackey, W.L. Brown, and R.S. Harris Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1 J. Virol. 85 2011 11220 11234
63. H. Huthoff, and M.H. Malim Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation J. Virol. 81 2007 3807 3815
64. H. Huthoff, F. Autore, S. Gallois-Montbrun, F. Fraternali, and M.H. Malim RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1 PLoS Pathog. 5 2009 e1000330
65. Y. Iwatani, D.S.B. Chan, F. Wang, K.S. Maynard, W. Sugiura, A.M. Gronenborn, I. Rouzina, M.C. Williams, K. Musier-Forsyth, and J.G. Levin Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G Nucleic Acids Res. 35 2007 7096 7108
66. S. Jäger, D.Y. Kim, J.F. Hultquist, K. Shindo, R.S. LaRue, E. Kwon, M. Li, B.D. Anderson, L. Yen, and D. Stanley et al. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection Nature 481 2012 371 375
67. A.A. Jaguva Vasudevan, M. Perkovic, Y. Bulliard, K. Cichutek, D. Trono, D. Häussinger, and C. Münk Prototype foamy virus Bet impairs the dimerization and cytosolic solubility of human APOBEC3G J. Virol. 87 2013 9030 9040
68. A. Jarmuz, A. Chester, J. Bayliss, J. Gisbourne, I. Dunham, J. Scott, and N. Navaratnam An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22 Genomics 79 2002 285 296
69. P. Jern, R.A. Russell, V.K. Pathak, and J.M. Coffin Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance PLoS Pathog. 5 2009 e1000367
70. E. Johansson, N. Mejlhede, J. Neuhard, and S. Larsen Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 A resolution Biochemistry 41 2002 2563 2570
71. S.M. Kaiser, and M. Emerman Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G J. Virol. 80 2006 875 882
72. R.C. Kalayjian, B. Lau, R.N. Mechekano, H.M. Crane, B. Rodriguez, R.A. Salata, Z. Krishnasami, J.H. Willig, J.N. Martin, and R.D. Moore et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care AIDS 26 2012 1907 1915
73. M. Kane, S.S. Yadav, J. Bitzegeio, S.B. Kutluay, T. Zang, S.J. Wilson, J.W. Schoggins, C.M. Rice, M. Yamashita, T. Hatziioannou, and P.D. Bieniasz MX2 is an interferon-induced inhibitor of HIV-1 infection Nature 502 2013 563 566
74. L.A. Kelley, and M.J.E. Sternberg Protein structure prediction on the Web: a case study using the Phyre server Nat. Protoc. 4 2009 363 371
75. I. Ketseoglou, A. Lukhwareni, K. Steegen, S. Carmona, W.S. Stevens, and M.A. Papathanasopoulos Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa AIDS Res. Hum. Retroviruses 30 2013 289 293
76. M.A. Khan, S. Kao, E. Miyagi, H. Takeuchi, R. Goila-Gaur, S. Opi, C.L. Gipson, T.G. Parslow, H. Ly, and K. Strebel Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes J. Virol. 79 2005 5870 5874
77. M.A. Khan, R. Goila-Gaur, S. Opi, E. Miyagi, H. Takeuchi, S. Kao, and K. Strebel Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions Retrovirology 4 2007 48
78. M.A. Khan, R. Goila-Gaur, S. Kao, E. Miyagi, R.C. Walker Jr., and K. Strebel Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization Retrovirology 6 2009 99
79. S. Kitamura, H. Ode, M. Nakashima, M. Imahashi, Y. Naganawa, T. Kurosawa, Y. Yokomaku, T. Yamane, N. Watanabe, and A. Suzuki et al. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding Nat. Struct. Mol. Biol. 19 2012 1005 1010
80. R.M. Kohli, S.R. Abrams, K.S. Gajula, R.W. Maul, P.J. Gearhart, and J.T. Stivers A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase J. Biol. Chem. 284 2009 22898 22904
81. T.C. Krzysiak, J. Jung, J. Thompson, D. Baker, and A.M. Gronenborn APOBEC2 is a monomer in solution: implications for APOBEC3G models Biochemistry 51 2012 2008 2017
82. M. Kumar, S. Sen, R.K. Gupta, D.N. Chaturbhuj, S.P. Tripathy, and R.S. Paranjape Prevalence of drug resistance in human immunodeficiency virus type 1 infected, treatment naïve children in Pune, India AIDS Res. Hum. Retroviruses 30 2014 294 298
83. N. Laguette, B. Sobhian, N. Casartelli, M. Ringeard, C. Chable-Bessia, E. Ségéral, A. Yatim, S. Emiliani, O. Schwartz, and M. Benkirane SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx Nature 474 2011 654 657
84. M.-A. Langlois, R.C.L. Beale, S.G. Conticello, and M.S. Neuberger Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities Nucleic Acids Res. 33 2005 1913 1923
85. R.S. LaRue, S.R. Jónsson, K.A.T. Silverstein, M. Lajoie, D. Bertrand, N. El-Mabrouk, I. Hötzel, V. Andrésdóttir, T.P.L. Smith, and R.S. Harris The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals BMC Mol. Biol. 9 2008 104
86. R.S. LaRue, V. Andrésdóttir, Y. Blanchard, S.G. Conticello, D. Derse, M. Emerman, W.C. Greene, S.R. Jónsson, N.R. Landau, and M. Löchelt et al. Guidelines for naming nonprimate APOBEC3 genes and proteins J. Virol. 83 2009 494 497
87. D. Lavens, F. Peelman, J. Van der Heyden, I. Uyttendaele, D. Catteeuw, A. Verhee, B. Van Schoubroeck, J. Kurth, S. Hallenberger, R. Clayton, and J. Tavernier Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis Nucleic Acids Res. 38 2010 1902 1912
88. D. Lecossier, F. Bouchonnet, F. Clavel, and A.J. Hance Hypermutation of HIV-1 DNA in the absence of the Vif protein Science 300 2003 1112
89. M. Letko, G. Silvestri, B.H. Hahn, F. Bibollet-Ruche, O. Gokcumen, V. Simon, and M. Ooms Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G J. Virol. 87 2013 11861 11871
90. X.-Y. Li, F. Guo, L. Zhang, L. Kleiman, and S. Cen APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription J. Biol. Chem. 282 2007 32065 32074
91. J.Z. Li, S. Gallien, T.D. Do, J.N. Martin, S. Deeks, D.R. Kuritzkes, and H. Hatano Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia Antimicrob. Agents Chemother. 56 2012 5998 6000
92. J. Li, Y. Chen, M. Li, M.A. Carpenter, R.M. McDougle, E.M. Luengas, P.J. Macdonald, R.S. Harris, and J.D. Mueller APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells J. Mol. Biol. 6 2014 1296 1307
93. M.T. Liddament, W.L. Brown, A.J. Schumacher, and R.S. Harris APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo Curr. Biol. 14 2004 1385 1391
94. R.P. Love, H. Xu, and L. Chelico Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A J. Biol. Chem. 287 2012 30812 30822
95. K. Luo, B. Liu, Z. Xiao, Y. Yu, X. Yu, R. Gorelick, and X.-F. Yu Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging J. Virol. 78 2004 11841 11852
96. K. Luo, T. Wang, B. Liu, C. Tian, Z. Xiao, J. Kappes, and X.-F. Yu Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation J. Virol. 81 2007 7238 7248
97. N. Madani, and D. Kabat An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein J. Virol. 72 1998 10251 10255
98. B. Mangeat, P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts Nature 424 2003 99 103
99. B. Mangeat, P. Turelli, S. Liao, and D. Trono A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action J. Biol. Chem. 279 2004 14481 14483
100. P.J. Masimba, E. Kituma, T. Klimkait, E. Horvath, M. Stoeckle, C. Hatz, E. Mossdorf, E. Mwaigomole, S. Khamis, and B. Jullu et al. Prevalence of drug resistance mutations and HIV type 1 subtypes in an HIV type 1-infected cohort in rural Tanzania AIDS Res. Hum. Retroviruses 29 2013 1229 1236
101. B. Max, and R. Sherer Management of the adverse effects of antiretroviral therapy and medication adherence Clin. Infect. Dis. 30 Suppl 2 2000 S96 S116
102. J.L. Mbisa, R. Barr, J.A. Thomas, N. Vandegraaff, I.J. Dorweiler, E.S. Svarovskaia, W.L. Brown, L.M. Mansky, R.J. Gorelick, and R.S. Harris et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration J. Virol. 81 2007 7099 7110
103. J.L. Mbisa, W. Bu, and V.K. Pathak APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms J. Virol. 84 2010 5250 5259
104. W.M. McDougall, and H.C. Smith Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity Biochem. Biophys. Res. Commun. 412 2011 612 617
105. W.M. McDougall, C. Okany, and H.C. Smith Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes J. Biol. Chem. 286 2011 30655 30661
106. A. Mehle, H. Wilson, C. Zhang, A.J. Brazier, M. McPike, E. Pery, and D. Gabuzda Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding J. Virol. 81 2007 13235 13241
107. E. Miyagi, C.R. Brown, S. Opi, M. Khan, R. Goila-Gaur, S. Kao, R.C. Walker Jr., V. Hirsch, and K. Strebel Stably expressed APOBEC3F has negligible antiviral activity J. Virol. 84 2010 11067 11075
108. K. Miyauchi, Y. Kim, O. Latinovic, V. Morozov, and G.B. Melikyan HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes Cell 137 2009 433 444
109. L.C.F. Mulder, M. Ooms, S. Majdak, J. Smedresman, C. Linscheid, A. Harari, A. Kunz, and V. Simon Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes J. Virol. 84 2010 9613 9617
110. C. Münk, B.-E.O. Jensen, J. Zielonka, D. Häussinger, and C. Kamp Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein Viruses 4 2012 3132 3161
111. R. Nathans, H. Cao, N. Sharova, A. Ali, M. Sharkey, R. Stranska, M. Stevenson, and T.M. Rana Small-molecule inhibition of HIV-1 Vif Nat. Biotechnol. 26 2008 1187 1192
112. F. Navarro, B. Bollman, H. Chen, R. König, Q. Yu, K. Chiles, and N.R. Landau Complementary function of the two catalytic domains of APOBEC3G Virology 333 2005 374 386
113. S.J.D. Neil, T. Zang, and P.D. Bieniasz Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu Nature 451 2008 425 430
114. E.N.C. Newman, R.K. Holmes, H.M. Craig, K.C. Klein, J.R. Lingappa, M.H. Malim, and A.M. Sheehy Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity Curr. Biol. 15 2005 166 170
115. M. Ooms, B. Brayton, M. Letko, S.M. Maio, C.D. Pilcher, F.M. Hecht, J.D. Barbour, and V. Simon HIV-1 Vif adaptation to human APOBEC3H haplotypes Cell Host Microbe 14 2013 411 421
116. M. Ooms, M. Letko, M. Binka, and V. Simon The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif PLoS ONE 8 2013 e57744
117. S. Opi, H. Takeuchi, S. Kao, M.A. Khan, E. Miyagi, R. Goila-Gaur, Y. Iwatani, J.G. Levin, and K. Strebel Monomeric APOBEC3G is catalytically active and has antiviral activity J. Virol. 80 2006 4673 4682
118. E. Pery, K.S. Rajendran, A.J. Brazier, and D. Gabuzda Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif J. Virol. 83 2009 2374 2381
119. C. Prochnow, R. Bransteitter, M.G. Klein, M.F. Goodman, and X.S. Chen The APOBEC-2 crystal structure and functional implications for the deaminase AID Nature 445 2007 447 451
120. A. Rathore, M.A. Carpenter, Ö. Demir, T. Ikeda, M. Li, N.M. Shaban, E.K. Law, D. Anokhin, W.L. Brown, R.E. Amaro, and R.S. Harris The local dinucleotide preference of APOBEC3G can be altered from 5′-CC to 5′-TC by a single amino acid substitution J. Mol. Biol. 425 2013 4442 4454
121. J.W. Rausch, L. Chelico, M.F. Goodman, and S.F. Le Grice Dissecting APOBEC3G substrate specificity by nucleoside analog interference J. Biol. Chem. 284 2009 7047 7058
122. E.W. Refsland, J.F. Hultquist, and R.S. Harris Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n PLoS Pathog. 8 2012 e1002800
123. T.H. Reingewertz, E. Britan-Rosich, S. Rotem-Bamberger, M. Viard, A. Jacobs, A. Miller, J.Y. Lee, J. Hwang, R. Blumenthal, M. Kotler, and A. Friedler Mapping the Vif-A3G interaction using peptide arrays: a basis for anti-HIV lead peptides Bioorg. Med. Chem. 21 2013 3523 3532
124. S.A. Roberts, M.S. Lawrence, L.J. Klimczak, S.A. Grimm, D. Fargo, P. Stojanov, A. Kiezun, G.V. Kryukov, S.L. Carter, and G. Saksena et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers Nat. Genet. 45 2013 970 976
125. R.A. Russell, and V.K. Pathak Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F J. Virol. 81 2007 8201 8210
126. J. Saadatmand, M. Niu, L. Kleiman, and F. Guo The contribution of the primer activation signal to differences between Gag- and NCp7-facilitated tRNA(Lys3) annealing in HIV-1 Virology 391 2009 334 341
127. H.A. Sadler, M.D. Stenglein, R.S. Harris, and L.M. Mansky APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis J. Virol. 84 2010 7396 7404
128. J.D. Salter, J. Krucinska, J. Raina, H.C. Smith, and J.E. Wedekind A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer self-association that has implications for anti-HIV function Biochemistry 48 2009 10685 10687
129. M. Santa-Marta, F.A. da Silva, A.M. Fonseca, and J. Goncalves HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation J. Biol. Chem. 280 2005 8765 8775
130. C. Schmitz, D. Marchant, S.J.D. Neil, K. Aubin, S. Reuter, M.T. Dittmar, and Á. McKnight Lv2, a novel postentry restriction, is mediated by both capsid and envelope J. Virol. 78 2004 2006 2016
131. B. Schröfelbauer, D. Chen, and N.R. Landau A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif) Proc. Natl. Acad. Sci. USA 101 2004 3927 3932
132. A.J. Schumacher, G. Haché, D.A. Macduff, W.L. Brown, and R.S. Harris The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction J. Virol. 82 2008 2652 2660
133. G. Senavirathne, M. Jaszczur, P.A. Auerbach, T.G. Upton, L. Chelico, M.F. Goodman, and D. Rueda Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution J. Biol. Chem. 287 2012 15826 15835
134. S.M.D. Shandilya, M.N.L. Nalam, E.A. Nalivaika, P.J. Gross, J.C. Valesano, K. Shindo, M. Li, M. Munson, W.E. Royer, and E. Harjes et al. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces Structure 18 2010 28 38
135. A.M. Sheehy, N.C. Gaddis, J.D. Choi, and M.H. Malim Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein Nature 418 2002 646 650
136. A.M. Sheehy, N.C. Gaddis, and M.H. Malim The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif Nat. Med. 9 2003 1404 1407
137. K. Shindo, A. Takaori-Kondo, M. Kobayashi, A. Abudu, K. Fukunaga, and T. Uchiyama The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity J. Biol. Chem. 278 2003 44412 44416
138. L.S. Shlyakhtenko, A.Y. Lushnikov, M. Li, L. Lackey, R.S. Harris, and Y.L. Lyubchenko Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G J. Biol. Chem. 286 2011 3387 3395
139. L.S. Shlyakhtenko, A.Y. Lushnikov, A. Miyagi, M. Li, R.S. Harris, and Y.L. Lyubchenko Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA Biochemistry 51 2012 6432 6440
140. F. Sievers, A. Wilm, D. Dineen, T.J. Gibson, K. Karplus, W. Li, R. Lopez, H. McWilliam, M. Remmert, and J. Söding et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega Mol. Syst. Biol. 7 2011 539
141. J.H.M. Simon, N.C. Gaddis, R.A.M. Fouchier, and M.H. Malim Evidence for a newly discovered cellular anti-HIV-1 phenotype Nat. Med. 4 1998 1397 1400
142. K.K. Siu, A. Sultana, F.C. Azimi, and J.E. Lee Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F Nat. Commun. 4 2013 2593
143. J.L. Smith, and V.K. Pathak Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif J. Virol. 84 2010 12599 12608
144. B.-H. Song, and J. Neuhard Chromosomal location, cloning and nucleotide sequence of the Bacillus subtilis cdd gene encoding cytidine/deoxycytidine deaminase Mol. Gen. Genet. 216 1989 462 468
145. V.B. Soros, W. Yonemoto, and W.C. Greene Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H PLoS Pathog. 3 2007 e15
146. B. Stauch, H. Hofmann, M. Perkovic, M. Weisel, F. Kopietz, K. Cichutek, C. Münk, and G. Schneider Model structure of APOBEC3C reveals a binding pocket modulating ribonucleic acid interaction required for encapsidation Proc. Natl. Acad. Sci. USA 106 2009 12079 12084
147. B.S. Stein, S.D. Gowda, J.D. Lifson, R.C. Penhallow, K.G. Bensch, and E.G. Engleman pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane Cell 49 1987 659 668
148. K.S. Stopak, Y.-L. Chiu, J. Kropp, R.M. Grant, and W.C. Greene Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells J. Biol. Chem. 282 2007 3539 3546
149. J.P. Stoye, N. Kaushik, S. Jeremiah, and S. Best Genetic map of the region surrounding the retrovirus restriction locus, Fv1, on mouse chromosome 4 Mamm. Genome 6 1995 31 36
150. M. Stremlau, C.M. Owens, M.J. Perron, M. Kiessling, P. Autissier, and J. Sodroski The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys Nature 427 2004 848 853
151. A.-H. Teh, M. Kimura, M. Yamamoto, N. Tanaka, I. Yamaguchi, and T. Kumasaka The 1.48 A resolution crystal structure of the homotetrameric cytidine deaminase from mouse Biochemistry 45 2006 7825 7833
152. M. Thiam, H. Diop-Ndiaye, A.D. Diouf, N. Vidal, O. Ndiaye, I. Ndiaye, N.F. Ngom-Gueye, S. Diallo, O.D. Diongue, and M. Camara et al. HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system J. Clin. Microbiol. 51 2013 578 584
153. C. Tian, X. Yu, W. Zhang, T. Wang, R. Xu, and X.-F. Yu Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F J. Virol. 80 2006 3112 3115
154. W.J. Towner, L. Xu, W.A. Leyden, M.A. Horberg, C.R. Chao, B. Tang, D.B. Klein, L.B. Hurley, C.P. Quesenberry Jr., and M.J. Silverberg The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction J. Acquir. Immune Defic. Syndr. 60 2012 321 327
155. T. Wang, C. Tian, W. Zhang, P.T.N. Sarkis, and X.-F. Yu Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging J. Mol. Biol. 375 2008 1098 1112
156. X. Wang, Y. Han, Y. Dang, W. Fu, T. Zhou, R.G. Ptak, and Y.-H. Zheng
157. X. Wang, Z. Ao, L. Chen, G. Kobinger, J. Peng, and X. Yao The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication J. Virol. 86 2012 3777 3786
158. J.E. Wedekind, R. Gillilan, A. Janda, J. Krucinska, J.D. Salter, R.P. Bennett, J. Raina, and H.C. Smith Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits J. Biol. Chem. 281 2006 38122 38126
159. M.J. Wichroski, K. Ichiyama, and T.M. Rana Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization J. Biol. Chem. 280 2005 8387 8396
160. Z. Xiao, E. Ehrlich, K. Luo, Y. Xiong, and X.-F. Yu Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G FASEB J. 21 2007 217 222
161. H. Xu, E. Chertova, J. Chen, D.E. Ott, J.D. Roser, W.-S. Hu, and V.K. Pathak Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions Virology 360 2007 247 256
162. T. Yamashita, K. Kamada, K. Hatcho, A. Adachi, and M. Nomaguchi Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F Microbes Infect. 10 2008 1142 1149
163. Y. Yang, F. Guo, S. Cen, and L. Kleiman Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F Virology 365 2007 92 100
164. Q. Yu, R. König, S. Pillai, K. Chiles, M. Kearney, S. Palmer, D. Richman, J.M. Coffin, and N.R. Landau Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome Nat. Struct. Mol. Biol. 11 2004 435 442
165. H. Zhang, B. Yang, R.J. Pomerantz, C. Zhang, S.C. Arunachalam, and L. Gao The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA Nature 424 2003 94 98
166. W. Zhang, J. Du, S.L. Evans, Y. Yu, and X.-F. Yu T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction Nature 481 2012 376 379
167. A. Zhen, T. Wang, K. Zhao, Y. Xiong, and X.-F. Yu A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity J. Virol. 84 2010 1902 1911
168. T. Zuo, D. Liu, W. Lv, X. Wang, J. Wang, M. Lv, W. Huang, J. Wu, H. Zhang, and H. Jin et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC J. Virol. 86 2012 5497 5507